Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure submitted a premarket approval partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency for the use of Optune in patients with newly diagnosed glioblastoma.
Source: BusinessWire-Primary

Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients